Delving into the Latest Updates on BioGaia Pharma AB with Synapse

概览

排名前五的药物类型	数量

益生菌	1
活菌制剂	1

关联

2

项与 BioGaia Pharma AB 相关的药物

Lactobacillus gasseri (BioGaia)

靶点-

作用机制

细菌替代物 [+1]

在研机构

BioGaia Pharma AB [+1]

原研机构

BioGaia AB

在研适应症-

非在研适应症-

最高研发阶段临床2期

首次获批国家/地区-

首次获批日期-

BGP-014

靶点-

作用机制

细菌替代物 [+1]

在研机构

BioGaia Pharma AB

原研机构

BioGaia Pharma AB

在研适应症

溃疡性结肠炎

非在研适应症-

最高研发阶段临床1/2期

首次获批国家/地区-

首次获批日期-

4

项与 BioGaia Pharma AB 相关的临床试验

NCT05118919 / Recruiting临床1/2期

A Randomised Placebo-controlled Safety Study of Lactobacillus Reuteri BGP-014 in Patients With Mild to Moderate Ulcerative Colitis

The objectives of this study are to evaluate the safety, tolerability and preliminary efficacy of Lactobacillus reuteri BGP-014 in mild to moderate active Ulcerative Colitis (UC) patients as an oral administered local treatment in addition to Standard of Care (SoC) treatment.

开始日期2022-02-09

申办/合作机构

BioGaia Pharma AB

NCT05133076 / Recruiting临床2期

A Randomized Placebo-controlled Study to Assess Safety and Preliminary Efficacy of BGP345A in Patients With Constipation Due to the Use of Opioid-based Medications for the Management of Chronic Non Cancer Pain

The purpose of this study is to assess safety and preliminary efficacy of BGP345A in patients with constipation due to the use of opioid-based medications for the management of chronic non cancer pain.

开始日期2022-01-20

申办/合作机构

BioGaia Pharma AB

[+1]

EUCTR2019-004578-25-SE / Unknown status临床1/2期

A randomised placebo-controlled safety study of Lactobacillus reuteri BGP-014 in patients with active mild to moderate ulcerative colitis

开始日期2021-07-09

申办/合作机构

BioGaia Pharma AB

100 项与 BioGaia Pharma AB 相关的临床结果

登录后查看更多信息

0 项与 BioGaia Pharma AB 相关的专利（医药）